{"url_path":"/sec/avxl/8-k/2026-08-11/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/1314052/0001731122-26-001042-index.html","accession_number":"0001731122-26-001042","cik":"0001314052","ticker":"AVXL","issuer_name":"ANAVEX LIFE SCIENCES CORP.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1314052/0001731122-26-001042-index.html","primary_entity_key":"0001314052","primary_entity_name":"ANAVEX LIFE SCIENCES CORP."},"word_count":165,"has_tables":true,"body_markdown":"**Item 7.01. Regulation FD Disclosure.**\n\n** **\n\nOn August 11, 2026, Anavex Life Sciences Corp. (“Anavex” or\nthe “Company”) issued a press release announcing the filing of the Company’s definitive proxy statement for its 2026\nAnnual Meeting of Stockholders (the “Press Release”). The Press Release includes an open letter to Anavex’s stockholders\nhighlighting, among other things, plans to refresh Anavex’s Board of Directors at the 2026 Annual Meeting of Stockholders.\n\n \n\nA copy of the Press Release is furnished as Exhibit 99.1 to this Current\nReport and is incorporated herein by reference.\n\n \n\nThe information included in this Item 7.01, including Exhibit 99.1, shall\nnot be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),\nor otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the\nSecurities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing."}